Sindrome.del.Ovario.Poliquistico

96 Síndrome del Ovario Poliquístico
23
Boots LR, Potter S, Potter HD, Azziz R.
Measurement of total serum testosterone
levels using commercially available
kits: high degree of between-kit variability.
Fertil Steril. 1998;69:286-92.
24
Azziz R, Sánchez LA, Knochenhauer ES,
Moran C, Lazenby J, Stephens KC, et al.
Androgen excess in women: experience
with over 1.000 consecutive patients. J
Clin Endocrinol Metab. 2004;89:453-62.
25
Ayala C, Steinberger E, Smith KD,
Rodríguez-Rigau LJ, Petak SM. Serum
testyosterone levels and reference ranges
in reproductive-age woman. Endocr
Pract. 1999;5:322-9.
26
Rosner W. Errors in the measurement of
plasma free testosterone. J Clin Endocrinol
Metab. 1997;82:2014-5.
27
Vermeulen A, Verdonck L, Kaufman JM.
A critical evaluation of simple methods
for the estimation of free testosterone in
serum. J Clin Endocrinol Metab. 1999;
84:3666-72.
28
Balen AH, Conway GS, Kaltsas G, Techatrasak
K, Manning PJ, West C, et al. Polycystic
ovary syndrome: the spectrum
of the disorder in 1.741 patients. Hum
Reprod. 1995;10:2107-11.
29
Ehrmann DA, Barnes RB, Rosenfield
RL. Polycystic ovary syndrome: a form
of functional ovarian hyperandrogenism
due to dysregulation of androgen secretion.
Endocrin Rev. 1995;16:322-53.
30
Ibáñez L, Potau N. Hiperandrogenismos
ováricos peripuberales. Cuad Med
Reprod. 1996;2:11-22.
31
Taylor AE. McCourt B, Martin K, Anderson
EJ, Adams J, Schoebfeld D, et al.
Determinants of abnormal gonadotropin
secretion in clinically defined women
with PCOS. J Clin Endocrinol Metab.
1997;82:2248-56.
32
Waldstreicher J, Santoro NF, Hall HJE,
Filicori M, Crowley WF. Hyperfunction
of the hypothalamic-pituitary axis in
women with polycystic ovarian disease:
indirect evidence of partial gonadotroph
desensitization. J Clin Endocrinol
Metab. 1988;66:165-72.
33
Fauser BC, Pache TD, Lamberts SW,
Hop WCJ, De Jong FH, Dahl KD. Serum
bioactive and immunoreactive LH and
FSH levels in women with cycle abnormalities,
with or without PCOD. J Clin
Endocrinol Metab. 1991;73:811-7.
34
Bloomgarden ZT. American Association
of Clinical Endocrinologists (AACE)
consensus conference on the insulin
resistance syndrome. Diabetes Care.
2003;26:1297-303.
35
Bloomgarden ZT. American Association
of Clinical Endocrinologists consensus
conference on the insulin resistance
syndrome. Diabetes Care. 2003;26:933-9.
36
Norman RJ, Masters L, Milner CR, Wang
JX, Davies MJ. Relative risk of conversion
from normoglycemia to impaired
glucose tolerance or non-insulin dependent
diabetes mellitus in polycystic ovary
syndrome. Hum Reprod. 2001;9:1995-8.
37
Legro RS. Polycystic ovary syndrome and
cardiovascular disease: a premature association?
Endocrine Rev. 2003;24:302-12.
38
Lord J, Wilkin T. Metformin in polycystic
ovary syndrome. Curr Opin Obstet
Gynecol. 2004;16:481-6.
39
Legro RS, Castracane VD, Kauffman RP.
Detecting Insulin Resistance in Polycystic
Ovary Syndrome: Purposes and
Pitfalls. Obstetr Gynecol Surv. 2004;59:
141-54.
40
American Diabetic Association. Consensus
Development Conference on Insulin
Resistance. Diabetes Care. 1998;21:310-4.
41
Legro RS, Finegood D, Dunaif A. A fasting
glucose to insulin ratio is a useful
measure of insulin sensivity in women
with polycystic ovary syndrome. J Clin
Endocrinol Metab. 1998;83:2694-8.
42
Katz, SS, Nambi K, Mather AD, Baron
DA, Follmann, Sullivan G, et al. Quantitative
insulin sensitivity check index:
a simple, accurate method for assessing
insulin sensitivity in humans. J Clin
Endocrinol Metab. 2000;85:2402-10.
43
Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF, Turner RC.